COR Therapeutics Announces Planned Presentation of Pursuit Study of Integrilin.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--August 22, 1997-- COR Therapeutics, Inc. (Nasdaq: CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) announced that initial results of the 10,948 patient PURSUIT trial of its investigational new drug INTEGRILIN(tm) (eptifibatide) are scheduled to be presented on Monday, August 25, 1997, at the 19th Congress of the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 50,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the impact of cardiovascular disease in Europe. in Stockholm. The Company plans to issue a press release concurrent with this presentation. COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary product research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· , deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. and restenosis. CONTACT: COR Therapeutics, Inc. Laura A. Brege Jacquelyn A. Jeffries 415/244-6893 or Burns McClellan, Inc. Lisa Burns (Investors) Jonathan M. Nugent Scott Storbo (Media) 212/213-0006 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion